Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Huntingtons Disease Treatment Market

Huntingtons Disease Treatment Market Trends

  • Report ID: GMI10732
  • Published Date: Aug 2024
  • Report Format: PDF

Huntington’s Disease Treatment Market Trends

  • Increased research and development activities are significantly driving the growth of the market.
     
  • Research into the genetic and molecular mechanisms underlying Huntington’s disease has provided deeper insights into how the mutated huntingtin protein gene affects brain function. This enhanced understanding enables scientists to identify potential therapeutic targets and develop more precise treatments.
     
  • Pharmaceutical companies are investing heavily in drug discovery and development to create new treatments for HD. This involves high-throughput screening of drug candidates, preclinical studies, and clinical trials.
     
  • For instance, Tominersen, formerly known as IONIS-HTT and RG6042, developed by Ionis Pharmaceuticals, is an investigational antisense drug currently in Phase 2 trials. It aims to address the root cause of Huntington’s disease by decreasing the production of all forms of the huntingtin protein (HTT), including the mutated variant (mHTT).
     
  • Thus, the increasing focus on developing drugs that can slow or halt disease progression, rather than merely alleviating symptoms, is driving innovation and growth in the market.
Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Huntington’s disease treatment industry size was USD 457.5 million in 2023 and will grow at 20.8% CAGR between 2024 and 2032, driven by the increasing prevalence of the disease and growing awareness about neurodegenerative disorders.

The tetrabenazine segment held 47.8% share in 2023, primarily due to its proven efficacy in managing chorea, a primary symptom of the disease.

North America Huntington’s disease treatment industry achieved USD 183.9 million in 2023, propelled by its advanced healthcare infrastructure and significant investments in research and development.

Bausch Health Companies Inc., CHEPLAPHARM Arzneimittel GmbH, Dr. Reddy’s Laboratories Ltd., H. Lundbeck A/S, Hikma Pharmaceuticals PLC, Lupin Limited, Neurocrine Biosciences, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Upsher-Smith Laboratories, LLC., among others.

Huntingtons Disease Treatment Market Scope

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 10
  • Tables & Figures: 204
  • Countries covered: 22
  • Pages: 112
 Download Free Sample